Premium
Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival
Author(s) -
Holmlund Camilla,
Haapasalo Hannu,
Yi Wei,
Raheem Olayinka,
Brännström Thomas,
Bragge Helena,
Henriksson Roger,
Hedman Håkan
Publication year - 2009
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/j.1440-1789.2008.00970.x
Subject(s) - oligodendroglioma , immunohistochemistry , oligodendroglial tumor , cytoplasm , immunocytochemistry , medicine , biology , pathology , gene , cancer research , glioma , astrocytoma , genetics
The three leucine‐rich repeats and immunoglobulin‐like domains (LRIG) genes encode integral membrane proteins. Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies. In astrocytic tumors, the subcellular distribution of LRIG proteins is associated with specific clinicopathological features and patient survival. The role of LRIG proteins in oligodendroglioma has not previously been studied. Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters. Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival. This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.